März

• Schaefers S, Kamili A, Hoffmann C, Cichutek S, Haag F, Polywka S, Bokemeyer C, Leypoldt L, Alsdorf W, Schulze zur Wiesch J, Weisel KC. BCMA×CD3 T-cell engager in a patient with penta-refractory multiple myeloma and HIV: A clinical and immunological report. Haematologica. 2024 Mar 28. doi: 10.3324/haematol.2023.284917.
• Noe S, Ivanova A, Johnsson-Oldenbüttel C, Schäfer G, Schewe CK, Hoffmann C. Immunological alterations with GLP-1 receptor agonists. HIV Medicine 2024, Mar 3. doi: 10.1111/hiv.13631

Februar

• Thiele RJ, Grünhagel B, Münchhoff M, Pujantell-Graell M, Jocham L, Düsedau A, Hennesen J, Hildebrandt H, Hagen SH, Sandfort D, Bunders MJ, Keppler OT, Hoffmann C, Altfeld M. Magnitude of Type I Interferon Responses by Plasmacytoid Dendritic Cells After TLR7 Stimulation Is Associated With Human Immunodeficiency Virus Type 1 (HIV-1) Reservoir Sizes in Cisgender Women With HIV-1 on Antiretroviral Therapy Get access Arrow. J Infect Dis 2024 Feb 22:jiae013. doi: 10.1093/infdis/jiae013. PMID: 38385222
• Kessel J, Rossaert AC, Lingscheid T, Grothe J, Harrer T, Wyen C, Tominski D, Bollinger T, Jehr AK, Kalbitz S, Hoffmann C, Cornely O, Koppe U, Stephan C, Rickerts V. Survival after cryptococcosis in Germany: A retrospective multicenter cohort study of patients diagnosed between 2004 and 2021. Int J Med Microbiol. 2024 Feb 16;314:151614. doi: 10.1016/j.ijmm.2024.151614. PMID: 38368645

Januar

• Schäfer G, Lübke R, Degen O, Mader M, Scheiter R, Wolski A, Addo MM, Schulze Zur Wiesch J, Pischke S. Lack of evidence of acute HEV infections as a sexually transmitted disease: Data from a German cohort of PrEP users. Braz J Infect Dis. 2024 Jan-Feb;28(1):103720. doi: 10.1016/j.bjid.2024.103720.

Oktober

• Schäfer G. [The HIV patient in primary care]. MMW Fortschr Med. 2023 Oct;165(Suppl 3):67-73. doi: 10.1007/s15006-023-2835-xx

September

• Schmidt D, Kollan C, Schewe K, Hanhoff N, Rüsenberg R, Friebe M, Schikowski T, Schink SB, Marcus U, Koppe U, Jansen K, Streeck H, Ottensmeyer P, An der Heiden M, Bannert N, M'Bayo R, Ceres M, Weber L, Sweers H, Schmidt AJ, Tietz H, Danan E, Bendig J, Kloep S, Neumann A, Valbert F, Wasem J, Bartmeyer B, Bremer V; NEPOS Studiengruppe. Evaluating the introduction of HIV pre-exposure prophylaxis as a benefit of statutory health insurance (EvE-PrEP): Highly effective protection against HIV without an increase in sexually transmitted infections. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2023 Sep;66(9):1008-1018. doi: 10.1007/s00103-023-03733-0. Epub 2023 Jul 12. PMID: 37436444
• González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masiá M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martínez E; NEAT 022 Study Group. Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir. J Antimicrob Chemother. 2023 Sep 5;78(9):2361-2365. doi: 10.1093/jac/dkad247. PMID: 37539492

August

• Hoffmann C, Hentrich M. Optimising treatment of HIV-associated Hodgkin lymphoma. Lancet Haematol. 2023 Aug;10(8):e563-e564. doi: 10.1016/S2352-3026(23)00177-1. PMID: 37532413
• Matthews H, Koval A, Völker K, Hertling S, Hoffmann C, Schäfer G, Unger S, Schulze Zur Wiesch J, Hüfner AD, Jordan S, Degen O, Schmiedel S. Treatment and Concomitant Infections in Refugees From the Ukraine With HIV. Dtsch Arztebl Int. 2023 Aug 7;120(31-32):540-541. doi: 10.3238/arztebl.m2023.0110. PMID: 37721143

Juli

• Schleenvoigt BT, Ankert J, Barten-Neiner G, Voit F, Suttorp N, Boesecke C, Hoffmann C, Stolz D, Pletz MW, Rohde G, Witzenrath M, Panning M, Essig A, Rupp J, Degen O, Stephan C; CAPNETZ Study Group. Pathogen spectrum of community acquired pneumonia in people living with HIV (PLWH) in the German CAPNETZ-Cohort. Infection. 2023 Jul 9. doi: 10.1007/s15010-023-02070-3. PMID: 37423969

Juni

• Schmidt D, Kollan C, Bartmeyer B, Bremer V, Schikowski T, Friebe M, Schellberg S, Scholten S, Bickel M, Hanhoff N, Rüsenberg R, Schewe K; NEPOS study group. Low incidence of HIV infection and decreasing incidence of sexually transmitted infections among PrEP users in 2020 in Germany. Infection. 2023 Jun;51(3):665-678. doi: 10.1007/s15010-022-01919-3. Epub 2022 Sep 27. PMID: 36168098

Mai

• Sempere A, Assoumou L, González-Cordón A, Waters L, Rusconi S, Domingo P, Gompels M, de Wit S, Raffi F, Stephan C, Masiá M, Rockstroh J, Katlama C, Behrens GMN, Moyle G, Johnson M, Fox J, Stellbrink HJ, Guaraldi G, Florence E, Esser S, Gatell J, Pozniak A, Martínez E; NEAT 022 Study Group. Incidence of hypertension and blood pressure changes in persons with HIV at high risk for cardiovascular disease switching from boosted protease inhibitors to dolutegravir: a post-hoc analysis of the 96-week randomised NEAT-022 trial. Clin Infect Dis. 2023 May 19:ciad297. doi: 10.1093/cid/ciad297. PMID: 37207617
• Sax PE, Arribas JR, Orkin C, Lazzarin A, Pozniak A, DeJesus E, Maggiolo F, Stellbrink HJ, Yazdanpanah Y, Acosta R, Huang H, Hindman JT, Martin H, Baeten JM, Wohl D; GS-US-380-1489 and GS-US-380-1490 study investigators. Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials. EClinicalMedicine. 2023 May 11;59:101991. doi: 10.1016/j.eclinm.2023.101991. eCollection 2023 May. PMID: 37200995
• Weimann L, Schäfer G, Matthews H, Florey M, Scheiter R, Hüfner A, Jordan S, Grenz M, Schmiedel S, Schulze Zur Wiesch J, Degen O, Koch T. Prospective Single-Center Cohort Study on HIV Pre-exposure Prophylaxis Reveals Transient but Relevant Elevations in Transaminase Levels in Some Participants Albeit Otherwise High Tolerability. J Acquir Immune Defic Syndr. 2023 May 1;93(1):e1-e3. doi: 10.1097/QAI.0000000000003170. PMID: 36881817 

April

• Hoffmann C, Jessen H, Wyen C, Grunwald S, Noe S, Teichmann J, Krauss AS, Kolarikal H, Scholten S, Schuler C, Bickel M, Roll C, Kreckel P, Köppe S, Straub M, Klausen G, Lenz J, Esser S, Jensen B, Rausch M, Unger S, Pauli R, Härter G, Müller M, Masuhr A, Schäfer G, Seybold U, Schellberg S, Schneider J, Monin MB, Wolf E, Spinner CD, Boesecke C. Clinical characteristics of monkeypox virus infections among men with and without HIV: A large outbreak cohort in Germany. HIV Med. 2023 Apr;24(4):389-397. doi: 10.1111/hiv.13378. PMID: 36059149

März

• Lauscher P, Hanhoff N, Valbert F, Schewe K, Koegl C, Bickel M, Hoffmann C, Stephan C, Pauli R, Preis S, Neumann A, Wolf E. Socio-demographic and psycho-social determinants of HIV late presentation in Germany - results from the FindHIV study. AIDS Care. 2023 Mar 13:1-11. doi: 10.1080/09540121.2023.2185196. Online ahead of print. PMID: 36912672
• Weimann L, Schäfer G, Matthews H, Maria F, Scheiter R, Hüfner A, Jordan S, Genz M, Schmiedel S, Schulze Zur Wiesch J, Degen O, Koch T. Prospective single center cohort study on HIV pre-exposure prophylaxis reveals transient but relevant elevations in transaminase levels in some participants albeit otherwise high tolerability. J Acquir Immune Defic Syndr. 2023 Mar 1. doi: 10.1097/QAI.0000000000003170. Online ahead of print. PMID: 36881817
• Waters L, Assoumou L, González-Cordón A, Rusconi S, Domingo P, Gompels M, de Wit S, Raffi F, Stephan C, Masiá M, Rockstroh J, Katlama C, Behrens GMN, Moyle G, Johnson M, Fox J, Stellbrink HJ, Guaraldi G, Florence E, Esser S, Gatell JM, Pozniak A, Martínez E; NEAT 022 Study Group. Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial. Clin Infect Dis. 2023 Mar 4;76(5):861-870. doi: 10.1093/cid/ciac827. PMID: 36259527

Januar

• Tusch ES, Ryom L, Fursa O, Peters L, Østergaard L, Florence E, Edwards S, Hoffmann C, Sambatakou H, Reiss P, Shahar E, Reikvam DH, Schmied B, Paduta D, Yakovlev A, Szlávik J, Ranin J, Zilmer K, Uždaviniene V, Pelchen-Matthews A, Mocroft A, Reekie J. Incidence and risk factors for suicide, death due to substance use, and violent/accidental death in people with HIV. AIDS. 2023 Jan 1;37(1):161-171. doi: 10.1097/QAD.0000000000003402. Epub 2022 Oct 11. PMID: 36250262
• Mocroft A, Geressu A, Beguelin C, Llibre JM, Lazarus JV, Tomazic J, Smidt J, Parczewski M, Brännström J, Sedlacek D, Degen O, van der Valk M, Paduta D, Flamholc L, Schmid P, Orkin C, Nielsen LN, Hoffmann C, Beniowski M, Oprea C, Begovac J, Peters L. The role of HIV/hepatitis B virus/hepatitis C virus RNA+ triple infection in end-stage liver disease and all-cause mortality in Europe. AIDS. 2023 Jan 1;37(1):91-103. doi: 10.1097/QAD.0000000000003406. Epub 2022 Oct 18. PMID: 36476454

Dezember

•  Maasoumy B, Ingiliz P, Spinner CD, Cordes C, Stellbrink HJ, Schulze Zur Wiesch J, Schneeweiß SM, Deterding K, Müller T, Kahlhöfer J, Dörge P, von Karpowitz M, Manns MP, Wedemeyer H, Cornberg M; HepNet Acute HCV-V Study Group. Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV-V study. JHEP Rep. 2022 Dec 16;5(3):100650. doi: 10.1016/j.jhepr.2022.100650. eCollection 2023 Mar. PMID: 36852107

Oktober

• Hoffmann C, Hentrich M, Tiemann M, Rosenwald A, Weber F, Willenbacher W, Hübel K. Recent Advances in Castleman Disease. Oncol Res Treat. 2022;45(11):693-704. doi: 10.1159/000526640. Epub 2022 Oct 11. PMID: 36219975
• Hoffmann C, Wechselberger T, Drexel H, Dertinger S, Dirnhofer S, Pierson SK, Fajgenbaum DC, Kessler A. Idiopathic Multicentric Castleman Disease Occurring Shortly after mRNA SARS-CoV-2 Vaccine. Vaccines (Basel). 2022 Oct 15;10(10):1725. doi: 10.3390/vaccines10101725. PMID: 36298590
• Waters L, Assoumou L, González-Cordón A, Rusconi S, Domingo P, Gompels M, de Wit S, Raffi F, Stephan C, Masiá M, Rockstroh J, Katlama C, Behrens GMN, Moyle G, Johnson M, Fox J, Stellbrink HJ, Guaraldi G, Florence E, Esser S, Gatell JM, Pozniak A, Martínez E. Limited weight impact after switching from boosted protease inhibitors to dolutegravir in persons with HIV with high cardiovascular risk: a post hoc analysis of the 96-week NEAT-022 randomized trial. Clin Infect Dis. 2022 Oct 19:ciac827. doi: 10.1093/cid/ciac827. Online ahead of print. PMID: 36259527
• Geretti AM, Blanco JL, Marcelin AG, Perno CF, Stellbrink HJ, Turner D, Zengin T. HIV DNA Sequencing to Detect Archived Antiretroviral Drug Resistance. Infect Dis Ther. 2022 Oct;11(5):1793-1803. doi: 10.1007/s40121-022-00676-y. Epub 2022 Aug 1. PMID: 35915392

September

• Hoffmann C, Jessen H, Wyen C, Grunwald S, Noe S, Teichmann J, Krauss AS, Kolarikal H, Scholten S, Schuler C, Bickel M, Roll C, Kreckel P, Köppe S, Straub M, Klausen G, Lenz J, Esser S, Jensen B, Rausch M, Unger S, Pauli R, Härter G, Müller M, Masuhr A, Schäfer G, Seybold U, Schellberg S, Schneider J, Monin MB, Wolf E, Spinner CD, Boesecke C. Clinical characteristics of monkeypox virus infections among men with and without HIV: A large outbreak cohort in Germany. HIV Med. 2022 Sep 4. doi: 10.1111/hiv.13378. Epub ahead of print. PMID: 36059149.
• Schmidt D, Kollan C, Bartmeyer B, Bremer V, Schikowski T, Friebe M, Schellberg S, Scholten S, Bickel M, Hanhoff N, Rüsenberg R, Schewe K; NEPOS study group. Low incidence of HIV infection and decreasing incidence of sexually transmitted infections among PrEP users in 2020 in Germany. Infection. 2022 Sep 27:1-14. doi: 10.1007/s15010-022-01919-3. Online ahead of print. PMID: 36168098

August

• Nörz D, Brehm TT, Tang HT, Grewe I, Hermanussen L, Matthews H, Pestel J, Degen O, Günther T, Grundhoff A, Fischer N, Addo MM, Jordan S, Hertling S, Unger S, Schäfer G, Schewe K, Hoffmann C, Aepfelbacher M, Pfefferle S, Schulze Zur Wiesch J, Schmiedel S, Lütgehetmann M. Clinical characteristics and comparison of longitudinal qPCR results from different specimen types in a cohort of ambulatory and hospitalized patients infected with monkeypox virus. J Clin Virol. 2022 Oct;155:105254. doi: 10.1016/j.jcv.2022.105254. Epub 2022 Aug 11. PMID: 36057206.
• Geretti AM, Blanco JL, Marcelin AG, Perno CF, Stellbrink HJ, Turner D, Zengin T. HIV DNA Sequencing to Detect Archived Antiretroviral Drug Resistance. Infect Dis Ther. 2022 Aug 1. doi: 10.1007/s40121-022-00676-y. Epub ahead of print. PMID: 35915392.
• Boesecke C, Monin MB, van Bremen K, Schlabe S, Hoffmann C. Severe monkeypox-virus infection in undiagnosed advanced HIV infection. Infection. 2022 Aug 15. doi: 10.1007/s15010-022-01901-z. Epub ahead of print. PMID: 35969365.
• Hoffmann C, Jessen H, Wyen C, Noe S, Kreckel P, Köppe S, Krauss AS, Schuler C, Bickel M, Lenz J, Scholten S, Klausen G, Lindhof HH, Jensen B, Glaunsinger T, Pauli R, Härter G, Radke B, Unger S, Marquardt S, Masuhr A, Esser S, Flettner TO, Schäfer G, Schneider J, Spinner CD, Boesecke C. Monkeypox in Germany–Initial Clinical Observations. Dtsch Arztebl Int. 2022 Aug 12;(Forthcoming):arztebl.m2022.0287. doi: 10.3238/arztebl.m2022.0287. PMID: 35912445.
• Thornhill JP, Barkati S, Walmsley S, Rockstroh J, Antinori A, Harrison LB, Palich R, Nori A, Reeves I, Habibi MS, Apea V, Boesecke C, Vandekerckhove L, Yakubovsky M, Sendagorta E, Blanco JL, Florence E, Moschese D, Maltez FM, Goorhuis A, Pourcher V, Migaud P, Noe S, Pintado C, Maggi F, Hansen AE, Hoffmann C, Lezama JI, Mussini C, Cattelan A, Makofane K, Tan D, Nozza S, Nemeth J, Klein MB, Orkin CM; SHARE-net Clinical Group. Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022. N Engl J Med. 2022 Aug 25;387(8):679-691. doi: 10.1056/NEJMoa2207323. Epub 2022 Jul 21. PMID: 35866746.

Juni

• Esser S, Schöfer H, Hoffmann C, Claßen J, Kreuter A, Leiter U, Oette M, Becker JC, Ziemer M, Mosthaf F, Sirokay J, Ugurel S, Potthoff A, Helbig D, Bierhoff E, Schulz TF, Brockmeyer NH, Grabbe S. S1 Guidelines for the Kaposi Sarcoma. J Dtsch Dermatol Ges. 2022 Jun;20(6):892-904. doi: 10.1111/ddg.14788. Epub 2022 Jun 3. PMID: 35657085.

Mai

• Segal-Maurer S, DeJesus E, Stellbrink HJ, Castagna A, Richmond GJ, Sinclair GI, Siripassorn K, Ruane PJ, Berhe M, Wang H, Margot NA, Dvory-Sobol H, Hyland RH, Brainard DM, Rhee MS, Baeten JM, Molina JM; CAPELLA Study Investigators. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection. N Engl J Med. 2022 May 12;386(19):1793-1803. doi: 10.1056/NEJMoa2115542. PMID: 35544387.
• Marquez LK, Ingiliz P, Boesecke C, Krznaric I, Schewe K, Lutz T, Mauss S, Christensen S, Rockstroh JK, Jain S, He F, Wertheim JO, Martin NK. Establishing a framework towards monitoring HCV microelimination among men who have sex with men living with HIV in Germany: A modeling analysis. PLoS One. 2022 May 12;17(5):e0267853. doi: 10.1371/journal.pone.0267853. eCollection 2022. PMID: 35551326

April

• Kolbe K, Wittner M, Hartjen P, Hüfner AD, Degen O, Ackermann C, Cords L, Stellbrink HJ, Haag F, Schulze Zur Wiesch J. Inversed Ratio of CD39/CD73 Expression on γδ T Cells in HIV Versus Healthy Controls Correlates With Immune Activation and Disease Progression. Front Immunol. 2022 Apr 22;13:867167. doi:10.3389/fimmu.2022.867167. PMID: 35529864; PMCID: PMC9074873.
• Schäfer G. So behandle ich Patienten mit entzündlich rheumatischen Erkrankungen bei HIV/AIDS mit DMARDs [This is how I treat patients with inflammatory rheumatic diseases and HIV/AIDS with DMARDs]. Z Rheumatol. 2022 May;81(4):332-334. German. doi: 10.1007/s00393-022-01202-8. Epub 2022 Mar 31. PMID: 35359175.

Januar

• Hentrich MU, Bower M, Daugaard G, Dieing A, Bickel M, Berretta M, Lesmeister F, Jurinovic V, Stoehr A, Heinzelbecker J, Krznaric I, Dieckmann KP, Necchi A, Maroto Rey P, Rockstroh JK, Brito M, Pfister D, Hoffmann C. Outcomes of men with HIV and germ cell cancer: Results from an international collaborative study. Cancer. 2022 Jan 15;128(2):260-268. doi: 10.1002/cncr.33928. Epub 2021 Sep 30. PMID: 34592009.

Dezember

• Monin M, Kümmerle T, Schneider J, Cordes C, Heiken H, Stellbrink HJ, Krznaric I, Scholten S, Jensen B, Jessen H, Obst W, Spornraft-Ragaller P, Khaykin P, Balogh A, Wolf E, Bidner H, Spinner CD, Boesecke C; DUALIS STUDY GROUP. Switching to a NRTI-free 2 drug regimen (2DR) -a sub-analysis of the 48 weeks DUALIS study on metabolic and renal changes. HIV Res Clin Pract. 2021 Dec 23;23(1):15-21. Epub 2022 Mar 2. PMID: 35234092 .
• Amele S, Sandri AK, Rodger A, Vandekerckhove L, Benfield T, Milinkovic A, Duvivier C, Stellbrink HJ, Sambatakou H, Chkhartishvili N, Caldeira L, Laguno M, Domingo P, Wandeler G, Gisinger M, Kuzovatova E, Dragovic G, Knysz B, Matulionyte R, Rockstroh JK, Lundgren JD, Mocroft A, Peters L; EuroSIDA study group. HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe. HIV Med. 2022 Jul;23(6):684-692. doi: 10.1111/hiv.13212. Epub 2021 Dec 9. PMID: 34882940.

Oktober

• Vigón L, Martínez-Román P, Rodríguez-Mora S, Torres M, Puertas MC, Mateos E, Salgado M, Navarro A, Sánchez-Conde M, Ambrosioni J, Cervero M, Wyen C, Hoffmann C, Miró JM, Alcamí J, Podzamczer D, García-Gutiérrez V, Martínez-Picado J, Briz V, Rosa López-Huertas M, Planelles V, Coiras M; Multidisciplinary Group of Study of HIV-1 Reservoir MGS-HIVRES. Provirus reactivation is impaired in HIV-1 infected individuals on treatment with dasatinib and antiretroviral therapy. Biochem Pharmacol. 2021 Oct;192:114666. doi: 10.1016/j.bcp.2021.114666. Epub 2021 Jun 26. PMID: 34186065.
• Erlandson KM, Carter CC, Melbourne K, Brown TT, Cohen C, Das M, Esser S, Huang H, Koethe JR, Martin H, McComsey GA, Orkin C, Post FA, Rockstroh JK, Sax PE, Stellbrink HJ, Waters L, Wei X, Lake JE. Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials. Clin Infect Dis. 2021 Oct 20;73(8):1440-1451. doi: 10.1093/cid/ciab444. PMID: 33987636.
• Orkin C, Bernal Morell E, Tan DHS, Katner H, Stellbrink HJ, Belonosova E, DeMoor R, Griffith S, Thiagarajah S, Van Solingen-Ristea R, Ford SL, Crauwels H, Patel P, Cutrell A, Smith KY, Vandermeulen K, Birmingham E, St Clair M, Spreen WR, D'Amico R. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study. Lancet HIV. 2021 Nov;8(11):e668-e678. doi: 10.1016/S2352-3018(21)00184-3. Epub 2021 Oct 14. PMID: 34656207.

August

• Wolf E, Boesecke C, Balogh A, Bidner H, Cordes C, Heiken H, Krznaric I, Kümmerle T, Stellbrink HJ, Schneider J, Spinner CD; DUALIS Study Group. Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance. AIDS Res Ther. 2021 Sep 8;18(1):58. doi: 10.1186/s12981-021-00384-6. PMID: 34496848; PMCID: PMC8425038.
• Smith GHR, Henry WK, Podzamczer D, Masiá MDM, Bettacchi CJ, Arasteh K, Jaeger H, Khuong-Josses MA, Montes-Ramírez ML, Stellbrink HJ, Yazdanpanah Y, Richmond GJ, Sutton KC, Zhang F, McCoig CC, St Clair MH, Vandermeulen K, Van Solingen- Ristea R, Smith KY, Margolis DA, Spreen WR. Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study. Open Forum Infect Dis. 2021 Aug 25;8(9):ofab439. doi: 10.1093/ofid/ofab439. PMID: 34557563; PMCID: PMC8454521.

Juni

• Hoffmann C. Versorgung von HIV-Patienten auch während der Pandemie sicherstellen [Ensure care for HIV patients even during the pandemic]. MMW Fortschr Med. 2021 Jun;163(Suppl 2):42-45. German. doi: 10.1007/s15006-021-9892-9. PMID: 34146317; PMCID: PMC8214386.

Mai

• Marquez LK, Ingiliz P, Boesecke C, Krznaric I, Schewe K, Lutz T, Mauss S, Christensen S, Rockstroh JK, Jain S, He F, Wertheim JO, Martin NK. Establishing a framework towards monitoring HCV microelimination among men who have sex with men living with HIV in Germany: A modeling analysis. PLoS One. 2022 May 12;17(5):e0267853. doi: 10.1371/journal.pone.0267853. PMID: 35551326; PMCID: PMC9098082.
• Olliges E, Bührlen B, Fischer F, Boesecke C, Kümmerle T, Schneider J, Weidlich S, Cordes C, Heiken H, Stellbrink HJ, Krznaric I, Scholten S, Jensen BE, Wolf E, Ronel J, Spinner CD, On Behalf Of The Dualis Study Group. Health-related quality-of-life in people living with HIV after switching to dual therapy with ritonavir-boosted darunavir + dolutegravir: a DUALIS sub-study. AIDS Care. 2022 Jun;34(6):698-707. doi: 10.1080/09540121.2021.1916873. Epub 2021 Apr 25. PMID: 33896276.
• Hentrich M, Müller M, Wyen C, Bogner J, Thomssen H, Wasmuth JC, Wolf T, Hoffmann C, Schommers P. Characteristics and outcome of human immunodeficiency virus (HIV)-associated primary effusion lymphoma as observed in the German HIV-related lymphoma cohort study. Br J Haematol. 2021 Aug;194(3):642-646. doi: 10.1111/bjh.17515. Epub 2021 May 7. PMID: 33959944.

Januar

• Funke B, Spinner CD, Esser S, Stellbrink HJ, Stoehr A, Wolf E, Koegl C, Bruening J, Witte V. High prevalence of recreational and illicit drug use in German people living with HIV with a potential for drug-drug interactions with antiretroviral therapy. Int J STD AIDS. 2021 Jan;32(1):75-82.
  doi: 10.1177/0956462420959169. Epub 2020 Nov 25. PMID: 33236659
• Valbert F, Wolf E, Preis S, Schellberg S, Schewe K, Hanhoff N, Mück B, Kögl C, Lauscher P, Wasem J, Neusser S, Neumann A. Understanding and avoiding late presentation for HIV diagnosis - study protocol of a trial using mixed methods (FindHIV). AIDS Care. 2021 Jan 23:1-5.
  doi: 10.1080/09540121.2021.1874276. Online ahead of print. PMID: 33487003
• Hoffmann C, Casado JL, Härter G, Vizcarra P, Moreno A, Cattaneo D, Meraviglia P, Spinner CD, Schabaz F, Grunwald S, Gervasoni C. Immune deficiency is a risk factor for severe COVID-19 in people living with HIV. HIV Med. 2020 Dec 27.
  doi: 10.1111/hiv.13037. Online ahead of print. PMID: 33368966
• Pierson SK, Khor JS, Ziglar J, Liu A, Floess K, NaPier E, Gorzewski AM, Tamakloe MA, Powers V, Akhter F, Haljasmaa E, Jayanthan R, Rubenstein A, Repasky M, Elenitoba-Johnson K, Ruth J, Jacobs B, Streetly M, Angenendt L, Patier JL, Ferrero S, Zinzani PL, Terriou L, Casper C, Jaffe E, Hoffmann C, Oksenhendler E, Fosså A, Srkalovic G, Chadburn A, Uldrick TS, Lim M, van Rhee F, Fajgenbaum DC. ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder. Cell Rep Med. 2020 Dec 22;1(9):100158.
  doi: 10.1016/j.xcrm.2020.100158. PMID: 33377129
• Fajgenbaum DC, Wu D, Goodman A, Wong R, Chadburn A, Nasta S, Srkalovic G, Mukherjee S, Leitch H, Jayanthan R, Ferrero S, Sato Y, Schey S, Dispenzieri A, Oksenhendler E, Zinzani PL, Lechowicz MJ, Hoffmann C, Pemmaraju N, Bagg A, Fossa A, Lim MS, van Rhee F; Castleman Disease Collaborative Network Scientific Advisory Board diagnostic criteria international working group and treatment guidelines international working group. Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. Am J Hematol. 2020 Dec;95(12):1553-1561.
  doi: 10.1002/ajh.25992. PMID: 32894785

Dezember

• Funke B, Spinner CD, Wolf E, Heiken H, Christensen S, Stellbrink HJ, Witte V. High prevalence of comorbidities and use of concomitant medication in treated people living with HIV in Germany - results of the BESIDE study. Int J STD AIDS. 2020 Dec 15:956462420942020.
  doi: 10.1177/0956462420942020. Epub ahead of print. PMID: 33323070.

November

• Hoffmann C, Wolf E. SARS-CoV-2 seroprevalence in Spain. Lancet. 2020 Nov 7;396(10261):1484.
  doi: 10.1016/S0140-6736(20)32272-8. PMID: 33160562

Oktober

• Stecher M, Schommers P, Kollan C, Stoll M, Kuhlendahl F, Stellbrink HJ, Wasmuth JC, Stephan C, Hamacher L, Lehmann C, Boesecke C, Bogner J, Esser S, Fritzsche C, Haberl A, Hoffmann C, Jensen B, Schwarze-Zander C, Platten M, Fätkenheuer G, Schmidt D, Gunsenheimer-Bartmeyer B, Vehreschild JJ; ClinSurv Study Group. Treatment modification after starting cART in people living with HIV: retrospective analysis of the German ClinSurv HIV Cohort 2005-2017.Infection. 2020 Oct;48(5):723-733.
  doi: 10.1007/s15010-020-01469-6. Epub 2020 Jul 1. PMID: 32613529; PMCID: PMC7519003.
• Hoffmann C, Wolf E. Older age groups and country-specific case fatality rates of COVID-19 in Europe, USA and Canada. Infection. 2020 Oct 24:1-6.
  doi: 10.1007/s15010-020-01538-w. PMID: 33098532
• Valbert F, Wolf E, Schewe K, Klauke S, Hanhoff N, Hoffmann C, Preis S, Pahmeier K, Wasem J, Neumann A. Cost of Human Immunodeficiency Virus (HIV) and Determinants of Healthcare Costs in HIV-Infected Treatment-Naive Patients Initiated on Antiretroviral Therapy in Germany: Experiences of the PROPHET Study. Value Health 2020; 23(10):1324–1331.
  doi: 10.1016/j.jval.2020.04.1836. PMID: 33032776
• Hoffmann C, Wolf E. The Low Case Fatality Rate of COVID-19 in Hong Kong Could Be Deceptive. Clin Infect Dis. 2020 Oct 29:ciaa1676.
  doi: 10.1093/cid/ciaa1676. PMID: 33119056
• van Bremen K, Hoffmann C, Mauss S, Lutz T, Ingiliz P, Spinner CD, Scholten S, Schwarze-Zander C, Berger F, Breitschwerdt S, Schneeweiss S, Busch F, Wasmuth JC, Fätkenheuer G, Lehmann C, Rockstroh JK, Boesecke C. Obstacles to HBV functional cure: Late presentation in HIV and its impact on HBV seroconversion in HIV/HBV coinfection. Liver Int. 2020 Oct 3.
  doi: 10.1111/liv.14684. PMID: 33012099

September

• Sax PE, Erlandson KM, Lake JE, Mccomsey GA, Orkin C, Esser S, Brown TT, Rockstroh JK, Wei X, Carter CC, Zhong L, Brainard DM, Melbourne K, Das M, Stellbrink HJ, Post FA, Waters L, Koethe JR. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clin Infect Dis. 2020 Sep 12;71(6):1379-1389.
  doi: 10.1093/cid/ciz999. PMID: 31606734; PMCID: PMC7486849.
• Fajgenbaum DC, Wu D, Goodman A, Wong R, Chadburn A, Nasta S, Srkalovic G, Mukherjee S, Leitch H, Jayanthan R, Ferrero S, Sato Y, Schey S, Dispenzieri A, Oksenhendler E, Zinzani PL, Lechowicz MJ, Hoffmann C, Pemmaraju N, Bagg A, Fossa A, Lim MS, van Rhee F and the Castleman Disease Collaborative Network Scientific Advisory Board diagnostic criteria international working group and treatment guidelines international working group. Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease. Am J Hematology. First published: 07 September 2020
  doi: 10.1002/ajh.25992. PMID: 32894785

August

• Spinner CD, Kümmerle T, Schneider J, Cordes C, Heiken H, Stellbrink HJ, Krznaric I, Scholten S, Jensen B, Wyen C, Viehweger M, Lehmann C, Sprinzl M, Stoehr A, Bickel M, Jessen H, Obst W, Spornraft-Ragaller P, Khaykin P, Wolf E, Boesecke C; DUALIS Study Group. Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study. Open Forum Infect Dis. 2020 Aug 13;7(9):ofaa356.
  doi: 10.1093/ofid/ofaa356. PMID: 32965277; PMCID: PMC7491710.
• Ingiliz P, Wehmeyer MH, Boesecke C, Schulze Zur Wiesch J, Schewe K, Lutz T, Baumgarten A, Simon KG, Hueppe D, Rockstroh JK, Mauss S, Christensen S; European AIDS Treatment Network (NEAT) Study Group; German Hepatitis C Cohort (GECCO) Study Group. Reinfection With the Hepatitis C Virus in Men Who Have Sex With Men After Successful Treatment With Direct-acting Antivirals in Germany: Current Incidence Rates, Compared With Rates During the Interferon Era. Clin Infect Dis. 2020 Aug 22;71(5):1248-1254.
  doi: 10.1093/cid/ciz949. PMID: 31562816

Juli

• Schürmann D, Hoffmann C, Stegemann MW, Ruwwe-Glösenkamp C, Gürtler G. HIV transmission by human bite. A case report and review of the literature. Implications for post-exposure prophylaxis. Infection 2020 Jul 26.
  doi: 10.1007/s15010-020-01477-6. PMID: 32715389

Juni

• Bickel M, Hoffmann C, Wolf E, Baumgarten A, Wyen C, Spinner CD, Jäger H, Postel N, Esser S, Mueller M, Stoehr A, Preis S, Klauke S, Schewe K; PROPHET study group of dagnae e.V.. High effectiveness of recommended first-line antiretroviral therapies in Germany: a nationwide, prospective cohort study. Infection. 2020 Jun;48(3):453-461.
  doi: 10.1007/s15010-020-01428-1. PMID: 32394345. Epub 2020 May 11.
• Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, Stephens JL, Stellbrink HJ, Wohl D, Maggiolo F, Thompson MA, Podzamczer D, Hagins D, Flamm JA, Brinson C, Clarke A, Huang H, Acosta R, Brainard DM, Collins SE, Martin H; GS-US-380-1489; GS-US-380-1490 study investigators. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir- containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. Lancet HIV. 2020 Jun;7(6):e389-e400.
  doi: 10.1016/S2352-3018(20)30099-0. PMID: 32504574.
• Hoffmann C. Compassionate Use of Remdesivir in Covid-19. N Engl J Med. 2020 Jun 18;382(25):e101.
  doi: 10.1056/NEJMc2015312. Epub 2020 May 15. PMID: 32412707

Mai

• Härter G, Spinner CD, Roider J, Bickel M, Krznaric I, Grunwald S, Schabaz F, Gillor D, Postel N, Mueller MC, Müller M, Römer K, Schewe K, Hoffmann C. Infection. COVID-19 in people living with human immunodeficiency virus: a case series of 33 patients. 2020 May 11:1-6.
  doi: 10.1007/s15010-020-01438-z. PMID: 32394344

April

• Hoffmann C, Schewe K, Fenske S, Buhk T, Sabranski M, Adam A, Hansen S, Stellbrink HJ. Short-term neuropsychiatric tolerability of bictegravir combined with FTC/TAF in clinical practice. Antivir Ther 2020 Apr 1.
  doi: 10.3851/IMP3351. PMID: 32235038.

März

• Stellbrink HJ, Lazzarin A, Woolley I, Llibre JM. The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV. HIV Med. 2020 Mar;21 Suppl 1:3-16.
  doi: 10.1111/hiv.12833. PMID: 32017355.

Februar

• Sabranski M, Erdbeer G, Sonntag I, Stoehr A, Horst HA, Plettenberg A, Lebherz L, Stellbrink HJ, Hoffmann C. Physical and mental health in HIV-infected patients with virological success and long-term exposure to antiretroviral therapy. AIDS Care. 2020 Feb 27:1-9.
  doi: 10.1080/09540121.2020.1733466. Epub ahead of print. PMID: 32106695.

November

• Schäfer G, Hoffmann C, Arasteh K, Schürmann D, Stephan C, Jensen B, Stoll M, Bogner JR, Faetkenheuer G, Rockstroh J, Klinker H, Härter G, Stöhr A, Degen O, Freiwald E, Hüfner A, Jordan S, Schulze Zur Wiesch J, Addo M, Lohse AW, van Lunzen J, Schmiedel S; IDEAL study group. Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii-pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study). AIDS Res Ther 2019, 16:34.
  doi: 10.1186/s12981-019-0250-2. PMID: 31729999

Oktober

• Martin NK, Jansen K, An der Heiden M, Boesecke C, Boyd A, Schewe K, Baumgarten A, Lutz T, Christensen S, Thielen A, Mauss S, Rockstroh JK, Skaathun B, Ingiliz P. Eliminating Hepatitis C Virus Among Human Immunodeficiency Virus-Infected Men Who Have Sex With Men in Berlin: A Modeling Analysis. J Infect Dis. 2019 Oct 8;220(10):1635-1644.
  doi: 10.1093/infdis/jiz367. PMID: 31301142

August

• Rizzardini G, Gori A, Miralles C, Olalla J, Molina JM, Raffi F, Kumar P, Antinori A, Ramgopal M, Stellbrink HJ, Das M, Chu H, Ram R, Garner W, Shao Y, Chuck SK, Piontkowsky D, Haubrich RH. Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen. AIDS. 2019 Aug 1;33(10):1583-1593.
  doi: 10.1097/QAD.0000000000002244. PMID: 31305329.

Juli

• Gupta SK, Post FA, Arribas JR, Eron JJ Jr, Wohl DA, Clarke AE, Sax PE, Stellbrink HJ, Esser S, Pozniak AL, Podzamczer D, Waters L, Orkin C, Rockstroh JK, Mudrikova T, Negredo E, Elion RA, Guo S, Zhong L, Carter C, Martin H, Brainard D, SenGupta D, Das M. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. AIDS. 2019 Jul 15;33(9):1455-1465.
  doi: 10.1097/QAD.0000000000002223. PMID: 30932951; PMCID: PMC6635043.
• Spinner CD, Lang GF, Boesecke C, Jessen H, Schewe K; German-Austrian PrEP consensus conference meeting 2018. Summary of German-Austrian HIV PrEP guideline. HIV Med. 2019 Jul;20(6):368-376.
  doi: 10.1111/hiv.12724. Epub 2019 May 29. PMID: 31140708
• Guaraldi G, Arends J, Buhk T, Cascio M, Curran A, Teofilo E, Berk GVD, Verger C. "Moving Fourth": A Vision Toward Achieving Healthy Living with HIV Beyond Viral Suppression. AIDS Rev. 2019;21(3):135-142.
  doi: 10.24875/AIDSRev.19000088. PMID: 31532396

Juni

• Stellbrink HJ, Arribas JR, Stephens JL, Albrecht H, Sax PE, Maggiolo F, Creticos C, Martorell CT, Wei X, Acosta R, Collins SE, Brainard D, Martin H. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019 Jun;6(6):e364-e372.
  doi: 10.1016/S2352-3018(19)30080-3. Epub 2019 May 5. PMID: 31068272.
• Gatell JM, Morales-Ramirez JO, Hagins DP, Thompson M, Arastéh K, Hoffmann C, Raffi F, Osiyemi O, Dretler R, Harvey C, Xu X, Plettenberg A, Smith DE, Portilla J, Rugina S, Kumar S, Frobose C, Wan H, Rodgers A, Hwang C, Teppler H. Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naïve adults with HIV-1 infection in a Phase 2b trial. Antiviral Therapy 2019, 2019 Jun 29.
  doi: 10.3851/IMP3323. PMID: 31355775

Mai

• Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, Corbelli GM,Estrada V, Geretti AM, Beloukas A, Raben D, Coll P, Antinori A, Nwokolo N, Rieger A, Prins JM, Blaxhult A, Weber R, Van Eeden A, Brockmeyer NH, Clarke A, Del Romero Guerrero J, Raffi F, Bogner JR, Wandeler G, Gerstoft J, Gutiérrez F, Brinkman K, Kitchen M, Ostergaard L, Leon A, Ristola M, Jessen H, Stellbrink HJ, Phillips AN, Lundgren J; PARTNER Study Group. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet. 2019 Jun 15;393(10189):2428-2438.
  doi: 10.1016/S0140-6736(19)30418-0. Epub 2019 May 2. PMID: 31056293; PMCID:PMC6584382.

Februar

• Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Stephan C, Rockstroh J, Giacomelli A, Vera J, Bernardino JI, Winston A, Saumoy M, Gras J, Katlama C, Pozniak AL; European Network for AIDS Treatment 022 (NEAT022) Study Group. Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study. Clin Infect Dis. 2019 Feb 1;68(4):597-606.
  doi: 10.1093/cid/ciy505. PMID: 29912307.
• van de Vijver DAMC, Richter AK, Boucher CAB, Gunsenheimer-Bartmeyer B, Kollan C, Nichols BE, Spinner CD, Wasem J, Schewe K, Neumann A. Cost-effectiveness and budget effect of pre-exposure prophylaxis for HIV-1 prevention in Germany from 2018 to 2058. Euro Surveill 2019 Feb;24(7):1800398.
  doi: 10.2807/1560-7917.ES.2019.24.7.1800398. PMID: 30782266
• Mauss S, Buendgens L, Christensen S, Ingiliz P, Berger F, Hüppe D, Simon KG, Lutz T, Schewe K, Boesecke C, Tacke F. Risk factors for remaining liver injury in patients with virological elimination of chronic hepatitis C. Z Gastroenterol. 2019 Feb;57(2):139-147.
  doi: 10.1055/a-0752-0514. Epub 2019 Feb 12. PMID: 30754058

Januar

• Hoffmann C, Llibre JM. Neuropsychiatric Adverse Events with Dolutegravir and Other Integrase Strand Transfer Inhibitors. AIDS Rev 2019, 21:4-10.
  doi: 10.24875/AIDSRev.19000023. PMID: 30899113